DK3058371T3 - Anvendelse af acamprosat til at modulere erk-1-2-aktivering i dyremodeller til fxs og asd og individer diagnosticeret med fxs og asd - Google Patents

Anvendelse af acamprosat til at modulere erk-1-2-aktivering i dyremodeller til fxs og asd og individer diagnosticeret med fxs og asd Download PDF

Info

Publication number
DK3058371T3
DK3058371T3 DK14854852.2T DK14854852T DK3058371T3 DK 3058371 T3 DK3058371 T3 DK 3058371T3 DK 14854852 T DK14854852 T DK 14854852T DK 3058371 T3 DK3058371 T3 DK 3058371T3
Authority
DK
Denmark
Prior art keywords
fxs
asd
acamprosate
activation
animal models
Prior art date
Application number
DK14854852.2T
Other languages
English (en)
Inventor
Craig Erickson
Debomoy Lahiri
Original Assignee
Univ Indiana Res & Tech Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Indiana Res & Tech Corp filed Critical Univ Indiana Res & Tech Corp
Application granted granted Critical
Publication of DK3058371T3 publication Critical patent/DK3058371T3/da

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701Details
    • G01N2333/4709Amyloid plaque core protein
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475Assays involving growth factors
    • G01N2333/48Nerve growth factor [NGF]
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90Enzymes; Proenzymes
    • G01N2333/91Transferases (2.)
    • G01N2333/912Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G01N2333/91205Phosphotransferases in general
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00Screening for compounds of potential therapeutic value
    • G01N2500/20Screening for compounds of potential therapeutic value cell-free systems
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/28Neurological disorders
    • G01N2800/2814Dementia; Cognitive disorders
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
DK14854852.2T 2013-10-14 2014-10-14 Anvendelse af acamprosat til at modulere erk-1-2-aktivering i dyremodeller til fxs og asd og individer diagnosticeret med fxs og asd DK3058371T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361890756P 2013-10-14 2013-10-14
PCT/US2014/060527 WO2015057736A1 (en) 2013-10-14 2014-10-14 Use of acamprosate to modulate erk 1-2 activation in animal models for fxs and asd and individuals diagnosed with fxs and asd

Publications (1)

Publication Number Publication Date
DK3058371T3 true DK3058371T3 (da) 2021-08-02

Family

ID=52828619

Family Applications (1)

Application Number Title Priority Date Filing Date
DK14854852.2T DK3058371T3 (da) 2013-10-14 2014-10-14 Anvendelse af acamprosat til at modulere erk-1-2-aktivering i dyremodeller til fxs og asd og individer diagnosticeret med fxs og asd

Country Status (11)

Country Link
US (2) US10634677B2 (da)
EP (1) EP3058371B1 (da)
JP (1) JP6637414B2 (da)
AU (1) AU2014337504B2 (da)
CA (1) CA2926645C (da)
DK (1) DK3058371T3 (da)
HU (1) HUE056551T2 (da)
PL (1) PL3058371T3 (da)
PT (1) PT3058371T (da)
RU (1) RU2696481C2 (da)
WO (1) WO2015057736A1 (da)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3058371T3 (da) 2013-10-14 2021-08-02 Univ Indiana Res & Tech Corp Anvendelse af acamprosat til at modulere erk-1-2-aktivering i dyremodeller til fxs og asd og individer diagnosticeret med fxs og asd
WO2017147044A1 (en) * 2016-02-22 2017-08-31 Indiana University Research And Technology Corporation Peptides and methods for treatment of neurodegenerative diseases

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6316635B1 (en) 1995-06-07 2001-11-13 Sugen, Inc. 2-indolinone derivatives as modulators of protein kinase activity
WO1997033585A1 (en) 1996-03-11 1997-09-18 Eli Lilly And Company Method for treating autism
BR9911908A (pt) 1998-07-06 2001-03-27 Nsgene As ácido nucléico, sequência de ácido nucléico, processos de usar um ácido nucléico, de usar o vetor, de fabricar o polipeptìdeo, de administrar o polipeptìdeo, de tratar uma doença ou distúrbio neurodegenerativos em um animal, de determinar se uma doença ou distúrbio neurodegenerativos em um animal, de produzir qualquer um polipeptìdeo, processo para identificar, isolar ou amplificar uma sequência de ácido nucléico de neublastina, de diagnosticar ou avaliar quanto a presença de uma doença ou distúrbio ou uma predisposiçãopara desnvolvê-los, para avaliar um polipeptìdeo de neublastina purificado ou um derivado ou fragmento deste ou um modulador da atividade dos precedentes quanto a atividade em tratar ou prevenir uma doença, de tratar um distúbio neurológico, de usar a sequência de um ou mais ácidos nucléicos, e para identificar um composto candidato que induza um efeito biológico mediado pela neuroblastina, vetor, célula transformada com ácido nucléico, polipeptìdeo, cmposição, anticorpo, gene sintético, e, conjunto.
US6593133B1 (en) 1998-07-06 2003-07-15 Nsgene A/S Neurotrophic factors
US6610681B1 (en) 1999-08-16 2003-08-26 Revaax Pharmaceuticals, Llc Neurotherapeutic clavulanate composition and method
SE0300586L (sv) 2003-03-04 2004-09-05 Forskarpatent I Syd Ab Diagnos av autism
DK3305776T3 (da) 2004-05-14 2019-12-09 Vertex Pharma Pyrrol-forbindelser som inhibitorer af erk-protein-kinaser og farmaceutiske sammensætninger, der indeholder disse forbindelser
US7595167B2 (en) 2005-10-11 2009-09-29 Blanchette Rockefeller Neurosciences Institute Alzheimer's disease-specific alterations of the Erk1/Erk2 phosphorylation ratio
US20080139472A1 (en) 2006-10-06 2008-06-12 The Regents Of The University Of California Upregulating bdnf levels to mitigate mental retardation
PL2083811T3 (pl) * 2006-11-22 2017-05-31 Clinical Research Associates, Llc Sposoby leczenia zespołu downa, zespołu łamliwego chromosomu x oraz autyzmu
BRPI0719459A2 (pt) 2006-12-22 2014-02-04 Genentech Inc "métodos para inibir a ligação do receptor de morte 6 (dr6) à proteína precursora amilóide (app), para o tratamento, para identificação de uma molécula de interesse que inibe a ligação do dr6 à app, para diagnosticar um paciente com, antagonista dr6 isolado, composição farmacêutica, artigo manufaturado e kit"
WO2008112772A2 (en) 2007-03-14 2008-09-18 Baylor Research Institute Gene expression in peripheral blood mononuclear cells from children with diabetes
US20090082464A1 (en) 2007-09-07 2009-03-26 Bernd Jandeleit Externally masked neopentyl sulfonyl ester cyclization release prodrugs of acamprosate, compositions thereof, and methods of use
US20090239888A1 (en) * 2008-02-12 2009-09-24 Wisconsin Alumni Research Foundation Methods for Inhibiting Amyloid Precursor Protein and Beta-Amyloid Production and Accumulation
MX2011000545A (es) * 2008-07-14 2011-02-24 Otonomy Inc Composiciones de liberacion controlada para la modulacion de apoptosis y metodos para el tratamiento de trastornos oticos.
AU2010213683B2 (en) 2009-02-12 2016-04-21 Indiana University Research & Technology Corporation Material and methods for treating developmental disorders including comorbid and idiopathic autism
US8008539B1 (en) 2009-03-19 2011-08-30 University Of South Florida Generation of transgenic human soluble amyloid precursor protein alpha expressing mice
US20130052644A1 (en) 2010-04-30 2013-02-28 Baltazar Gomez-Mancilla Predictive Markers Useful in the Treatment of Fragile X Syndrome (FXS)
US20110294879A1 (en) * 2010-05-28 2011-12-01 Xenoport, Inc. Method of treatment of fragile x syndrome, down's syndrome, autism and related disorders
CA2808660A1 (en) 2010-08-19 2012-02-23 Blanchette Rockefeller Neurosciences Institute Treatment of cognitive disorders associated with abnormal dendritic spines using pkc activators
RU2465273C2 (ru) 2010-08-31 2012-10-27 Общество С Ограниченной Ответственностью "Биофарм-Меморейн" ГЕТЕРОЦИКЛИЧЕСКИЕ НИЗКОМОЛЕКУЛЯРНЫЕ sAPP-МИМЕТИКИ, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, СПОСОБЫ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ
AU2013293167B2 (en) 2012-07-22 2019-04-18 Indiana University Research And Technology Corporation Modulation sAPP, sAPP alpha and BDNF levels in individuals diagnosed with FXS and ASD
DK3058371T3 (da) 2013-10-14 2021-08-02 Univ Indiana Res & Tech Corp Anvendelse af acamprosat til at modulere erk-1-2-aktivering i dyremodeller til fxs og asd og individer diagnosticeret med fxs og asd

Also Published As

Publication number Publication date
US20160266120A1 (en) 2016-09-15
RU2016118551A (ru) 2017-11-21
HUE056551T2 (hu) 2022-02-28
WO2015057736A1 (en) 2015-04-23
EP3058371B1 (en) 2021-06-16
US20200225233A1 (en) 2020-07-16
PL3058371T3 (pl) 2021-11-08
US11733243B2 (en) 2023-08-22
CA2926645C (en) 2022-10-25
AU2014337504B2 (en) 2020-01-30
EP3058371A4 (en) 2017-04-19
JP6637414B2 (ja) 2020-01-29
US10634677B2 (en) 2020-04-28
PT3058371T (pt) 2021-07-26
RU2016118551A3 (da) 2018-07-24
RU2696481C2 (ru) 2019-08-02
JP2016536293A (ja) 2016-11-24
CA2926645A1 (en) 2015-04-23
EP3058371A1 (en) 2016-08-24

Similar Documents

Publication Publication Date Title
IL290613A (en) Humanized or chimeric cd3 antibodies
DK3071696T3 (da) C/ebp alfa kort aktiverings-rna-sammensætninger og fremgangsmåder til anvendelse
DK3086807T3 (da) Antistoffer og fremgangsmåder til anvendelse
IL242825B (en) Systems and methods for diagnosis of depression and other medical conditions
PL3613439T3 (pl) Chimeryczny receptor antygenowy i sposoby jego zastosowania
DK3736292T3 (da) Anti-CD3-antistoffer og fremgangsmåder til anvendelse
EP2948848A4 (en) PARALLEL TRACKING FOR PERFORMANCE AND DETAIL
KR102195650B9 (ko) 통합된 폐쇄 장치 구성요소 및 방법
DK3079719T3 (da) ANTI-SIGLEC-8-antistoffer og fremgangsmåder til anvendelse deraf
PL3053071T3 (pl) Metody i procesy nieinwazyjnej oceny zmienności genetycznych
DK3022707T3 (da) Systemer og fremgangsmåder til at monitorere bevægelse af sygdomsfelt
DK2844672T3 (da) Humane antistoffer over for Fel d1 og fremgangsmåder til anvendelse deraf
EP3794941C0 (en) ANIMAL MODELS AND THERAPEUTIC MOLECULES
HRP20170840T1 (hr) Supstituirani ksantini i metode njihove uporabe
DK3090068T3 (da) Fremgangsmåde og kit til ikke-invasiv detektering af egfr-genmutationer
GEAP201814045A (en) Methods for fixing hair and skin
DK2964767T3 (da) Toksingener og fremgangsmåder til anvendelse deraf
IL244590A0 (en) Anti-epcam antibodies and methods of use
IL244200A0 (en) Nsaid and sigma receptor ligand combinations
EP3744284C0 (en) HEAD AND JAW IMMOBILIZATION DEVICE
BR112015002610A2 (pt) modelo animal de obesidade e métodos de sua fabricação e uso
IL246658B (en) Systems and methods for diagnosing sleep
DK3560937T3 (da) Fremgangsmåder til fremstilling af 18f-mærkede psma-målrettede billeddannelsesmidler og diagnostiske fremgangsmåder dermed
DK3029038T3 (da) Tetrazolinonforbindelse og anvendelse deraf
EP2989432C0 (en) IMAGING APPARATUS AND METHOD